$50M/Q is a vast overestimation. Multiply that by half, subtract out Nevada tax which I bet is extremely heavy on the sale of semi-illegal drug, finally subtract out the cost for raw material, labor, and administration. Not sure how much will be left for increasing share holders' value.
As a startup, their focus will be on expansion and less on building share holders' value, which means we won't see any net profit any time soon.